Sun Pharma to present long-term UNLOXCYT data in advanced CSCC at ESMO 2026
Sun Pharma will present updated long-term results from the CK-301-101 trial of UNLOXCYT (cosibelimab-ipdl) in advanced CSCC at the ESMO Congress in Madrid on 24 October 2026.
By ScoutQuest · · 1 min read
- Complete response (locally advanced)
- 34% of locally advanced CSCC patients had a complete response
- Complete response (metastatic)
- 17%-21% of metastatic patients did
- Objective response rates by cohort
- 51.3% in Group 1, 53.1% in Group 2 and 44.4% in Group 3
- Release
- Press release
🏭 The ESMO abstract expands the pivotal CK-301-101 analysis to 205 patients across three advanced CSCC cohorts using centrally reviewed data.
📌 Objective response rates in the three cohorts were 51.3% in Group 1, 53.1% in Group 2 and 44.4% in Group 3.
📌 Among responders, the estimated probability of remaining in response at two years ranged from 69% to 82% across the three cohorts.
📌 Sun Pharma says the safety profile remained consistent with previous analyses, with no grade 4 immune-related adverse events or irAEs leading to death.
Also from Sun Pharmaceutical Industries
UNLOXCYT elevated to NCCN Category 2A option for locally advanced CSCC
20 Oct 2026
Sun Pharma to announce Q2 results on 30 October 2026; earnings call at 6:30 pm IST
15 Oct 2026
Board meeting on 30 October 2026 to consider Unaudited Q2/H1 FY27 results; trading window closed
14 Oct 2026
More numbers
- Complete response rate, locally advanced CSCC34%
- Complete response rate, metastatic CSCC (range)17%-21%
- Median overall survival, Group 137.2 months
- Grade 3 immune-related adverse events2.9%
- Objective response rate, Group 151.3%
- Objective response rate, Group 253.1%
- Objective response rate, Group 344.4%
- Patients in ESMO abstract analysis205 patients
- Estimated probability of response at two years, lower end69%
- Estimated probability of response at two years, upper end82%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.